VX-407

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Phase 1OralAutosomal Dominant Polycystic Kidney Disease

59 competitors in Phase 1

#DrugCompanyPhaseTrials

1

Fludara

Sanofi

Phase 2

42

Rituxan

Roche

Phase 2

43

Venclexta

AbbVie

Phase 2

24

Cytoxan

BBaxter Healthcare Corporation

Phase 2

55

Erbitux

IImclone

Phase 2

36

Rayos

RRoxane Laboratories

Phase 2

17

Navitoclax

AbbVie

Phase 2

18

Yervoy

Bristol-Myers Squibb

Phase 1

19

VX-407

Vertex Pharmaceuticals

Phase 2

210

Benznidazole

CCorestemchemon, Inc.

Phase 1

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Phase 12 trials

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Completed·Vertex Pharmaceuticals·Phase 1·NCT06345755·159 enrolled

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Active, not recruiting·Vertex Pharmaceuticals·Phase 1·NCT07022119·32 enrolled

Autosomal Dominant Polycystic Kidney Disease2 trials

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants

Active, not recruiting·Vertex Pharmaceuticals·Phase 2·NCT07161037·26 enrolled

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Not yet recruiting·Vertex Pharmaceuticals·Phase 1·NCT07792408·148 enrolled

Oral1 trial

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Active, not recruiting·Vertex Pharmaceuticals·Phase 1·NCT07074327·74 enrolled

Details

Drug Info

Related News